c-Met/HGF Receptor in Melanoma Progression
Author Information
Author(s): P.G. Natali, M.R. Nicotra, M.F. Di Renzo, M. Prat, A. Bigotti, R. Cavalieri, P.M. Comoglio
Primary Institution: Regina Elena Cancer Institute
Hypothesis
The expression of the c-Met/HGF receptor is related to the progression of malignant melanoma.
Conclusion
The study found that the c-Met/HGF receptor is expressed at late stages of melanoma progression, particularly in metastatic lesions.
Supporting Evidence
- The c-MET receptor was undetectable in benign melanocytic lesions.
- Only four out of 23 primary melanomas expressed the c-MET receptor.
- 17 out of 44 metastatic lesions showed significant expression of the c-MET receptor.
Takeaway
This study looked at how a specific receptor related to cancer is found more in advanced melanoma cases, suggesting it might help the cancer spread.
Methodology
The study used immunohistochemistry to analyze tissue samples from benign and malignant melanocytic lesions.
Limitations
The study did not find a correlation between c-Met expression and pigmentation levels in melanoma.
Participant Demographics
The study included samples from human melanocytic lesions, including benign nevi, primary melanomas, and metastatic lesions.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website